The PROSPER trial is a Phase 2 clinical study evaluating FNP-223 (formerly ASN-561), an oral O-GlcNAcase (OGA) inhibitor developed by Ferrer International, in patients with progressive supranuclear palsy (PSP). This is the largest dedicated PSP trial for an OGA inhibitor and one of the few disease-modification trials in 4R-tauopathies[1].
Progressive Supranuclear Palsy represents one of the most challenging neurodegenerative conditions to treat. Unlike Alzheimer's disease, which has seen numerous disease-modifying approaches reach late-stage testing, PSP has remained largely without disease-modifying options. The PROSPER trial represents a bold attempt to address this unmet need by targeting the fundamental pathological process of tau aggregation through O-GlcNAcylation enhancement.
Tau Isoforms and Disease Specificity
The tau protein exists in six isoforms in the human brain, generated by alternative splicing of the MAPT gene:
| Isoform | Microtubule Binding Repeats | Brain Distribution | Disease Association |
|---|---|---|---|
| 3N-0N | 3R | Fetal brain | Not normally expressed |
| 3N-1N | 3R | Adult brain (low) | CBD, PiD |
| 3N-2N | 3R | Adult brain | CBD, PiD |
| 4N-0N | 4R | Adult brain (high) | PSP, CBD |
| 4N-1N | 4R | Adult brain (high) | PSP, CBD |
| 4N-2N | 4R | Adult brain (high) | PSP, CBD |
In healthy adult brain, approximately equal amounts of 3R and 4R tau are present. However, in PSP and corticobasal degeneration (CBD), there is a selective increase in 4R tau isoforms, making these disorders "4R-tauopathies." This isoform shift is thought to result from dysregulation of tau exon 10 splicing.
Why 4R Tau is Pathological
The 4R tau isoforms have several properties that promote aggregation:
Approved Treatments
| Treatment | Mechanism | Effect | Limitation |
|---|---|---|---|
| Levodopa | Dopamine replacement | Modest, transient | Limited benefit in PSP |
| Botulinum toxin | Muscle relaxation | Reduces dystonia | Local injection only |
| Amantadine | NMDA antagonist | May help some | Variable response |
| Speech therapy | Rehabilitation | Symptomatic | Limited impact on progression |
Investigational Approaches Under Development
| Approach | Target | Company | Status |
|---|---|---|---|
| FNP-223 | OGA inhibitor | Ferrer | Phase 2 |
| LY-3372689 | OGA inhibitor | Eli Lilly | Phase 2 |
| BIIB080 | ASO (tau) | Biogen | Phase 1/2 |
| E2814 | Tau aggregation inhibitor | Eisai | Phase 2 |
| Gantenerumab | Anti-tau antibody | Roche | Phase 3 (AD/PSP) |
The failure of numerous tau-targeted approaches in clinical trials highlights the challenge of PSP therapy. The OGA inhibition approach represents a fundamentally different strategy from antibody-based or antisense approaches.
Historical Development
The O-GlcNAcylation hypothesis for treating tauopathies developed over several decades:
| Year | Development | Key Finding |
|---|---|---|
| 1984 | O-GlcNAc discovered | First O-linked glycosylation on nuclear proteins |
| 2000 | Tau O-GlcNAc identified | Shows tau is modified by O-GlcNAc |
| 2001 | Competition demonstrated | O-GlcNAc and phosphate compete for same sites |
| 2006 | Reduction in AD brain | O-GlcNAc levels reduced in AD |
| 2008 | First OGA inhibitors | Small molecules increase O-GlcNAc |
| 2012 | Preclinical efficacy | OGA inhibitors reduce tau pathology |
| 2018 | Phase 1 completed | First OGA inhibitor in humans |
| 2024 | PROSPER initiated | Largest PSP OGA trial |
This progression from basic discovery to clinical trial represents 20 years of research investment. The PROSPER trial represents the culmination of this effort specifically for PSP.
Mechanistic Insights
The balance between phosphorylation and O-GlcNAcylation determines tau's functional state. Disease states shift this balance toward hyperphosphorylation, leading to aggregation.
| Parameter | Value |
|---|---|
| Trial ID | NCT06355531 |
| Phase | Phase 2 |
| Status | Active, not recruiting |
| Enrollment | 241 patients |
| Sponsor | Ferrer Internacional S.A. |
| Start Date | July 2024 |
| Completion Date | November 2026 |
| Results Expected | Late 2026 / Early 2027 |
| Sites | 44 sites across EU, UK, and US |
PSP is a 4R-tauopathy characterized by:
O-GlcNAcylation is a post-translational modification where N-acetylglucosamine is added to serine/threonine residues on proteins. This modification competes with phosphorylation at the same sites:
Mechanism:
Why OGA inhibition works:
FNP-223 (formerly ASN-561) is a potent, selective OGA inhibitor:
| Parameter | Value | Clinical Implication |
|---|---|---|
| Oral Bioavailability | ~60% | Suitable for chronic dosing |
| Tmax | 2-4 hours | Twice daily dosing feasible |
| Half-life | 8-12 hours | Steady-state in 2-3 days |
| Brain Penetration | High (Kpuu > 1.0) | Central target engagement |
| Protein Binding | Low-moderate | Predictable exposure |
| Metabolism | Liver (CYP450) | Drug interaction potential |
| Excretion | Renal (60%) | Renal dosing consideration |
Dose-Finding Rationale
The PROSPER trial employs a dose-finding design:
| Dose Level | Rationale |
|---|---|
| Low dose | Minimum target engagement |
| Mid dose | Optimal therapeutic range |
| High dose | Maximum effect + safety margin |
Expected CSF O-GlcNAc Response
Preclinical models predicted:
Target Engagement
| Biomarker | Sample | Method | Engagement Threshold |
|---|---|---|---|
| CSF O-GlcNAc | CSF | MS/MS | >30% increase |
| Blood O-GlcNAc | Plasma | WB | >50% increase |
| OGA activity | CSF | Enzymatic | >50% inhibition |
Disease Modification Markers
| Marker | Sample | Expected Direction |
|---|---|---|
| NfL | Plasma | Decrease (less neuroaxonal injury) |
| p-tau181 | CSF/Plasma | Stable or decrease |
| Total tau | CSF | Decrease (reduced release) |
| Biomarker | Sample | Purpose |
|---|---|---|
| CSF O-GlcNAc | CSF | Direct measurement of target engagement |
| Blood O-GlcNAc | Plasma | Peripheral biomarker for pharmacodynamics |
| CSF O-GlcNAcase activity | CSF | Enzyme inhibition confirmation |
| Biomarker | Sample | Purpose |
|---|---|---|
| Neurofilament light chain (NfL) | Plasma | Axonal injury marker |
| p-tau181 | CSF/Plasma | Tau pathology burden |
| p-tau217 | Plasma | Tau phosphorylation state |
| Tau PET | PET imaging | Regional tau accumulation |
Power Analysis
| Parameter | Value | Rationale |
|---|---|---|
| Expected treatment effect | 30% slowing | Meaningful clinical difference |
| Alpha | 0.05 (two-sided) | Standard significance level |
| Power | 80% | Adequate power for Phase 2 |
| Dropout rate | 20% | Account for PSP progression |
| Total sample | 241 | Provides 80% power |
Assumptions
Primary Analysis
| Method | Application |
|---|---|
| Mixed model repeated measures | Primary efficacy |
| ANCOVA | Sensitivity analyses |
| Responder analysis | Clinical relevance |
Time Points
| Visit | Timing | Primary Analysis |
|---|---|---|
| Baseline | Week 0 | Covariate |
| Week 12 | 3 months | PK/PD |
| Week 26 | 6 months | Interim |
| Week 52 | 12 months | Primary endpoint |
Biomarker Analyses
CSF O-GlcNAc
NfL trajectory
Neuroimaging
Subgroup Analyses
| Subgroup | Primary Comparisons |
|---|---|
| Age (<65 vs ≥65) | Treatment-by-age interaction |
| Disease duration (<2 vs >2 years) | Treatment-by-duration |
| Baseline severity (PSPRS <35 vs ≥35) | Treatment-by-severity |
| Prior treatment exposure | Effect modification |
Expected Adverse Events
| Frequency | Event | Expected Rate | Management |
|---|---|---|---|
| Common | Gastrointestinal | 20-30% | Dose adjustment |
| Common | Headache | 10-15% | Supportive care |
| Uncommon | Elevated LFTs | 3-5% | Dose hold/monitor |
| Rare | Serious hepatic | <1% | Discontinue |
Stopping Rules
| Criterion | Action |
|---|---|
| ALT/AST >3x ULN | Hold, monitoring |
| ALT/AST >5x ULN | Discontinue |
| Serious hepatic event | Discontinue |
| Tolerability concerns | Dose reduction |
Renal Impairment
| Function | Dose Adjustment |
|---|---|
| Mild | No adjustment |
| Moderate | Reduce 25-50% |
| Severe | Not studied |
Hepatic Impairment
| Function | Dose Adjustment |
|---|---|
| Mild | No adjustment |
| Moderate | Reduce 50% |
| Severe | Avoid |
Requirements
| Criterion | Requirement |
|---|---|
| PSP experience | >50 patients evaluated |
| Neurologist | Movement disorder specialist |
| Imaging | MRI capable |
| Lab | GCP certified |
| Recruitment | Historical enrollment rate |
United Kingdom
| Site | Key Personnel | Expertise |
|---|---|---|
| UCL Queen Square | Prof. Kailash Bhatia | PSP clinical lead |
| Oxford | Prof. Christopher Churchman | Clinical trials |
| Cambridge | Dr. James Boxer | Biomarkers |
Germany
| Site | Key Personnel | Expertise |
|---|---|---|
| Munich (LMU) | Prof. Günter Höglinger | PSP research |
| Berlin (Charité) | Prof. Andreas Hermann | Clinical |
| Tübingen | Prof. Wassili Tzavelis | Imaging |
United States
| Site | Key Personnel | Expertise |
|---|---|---|
| UCLA | Prof. Jeff Bronstein | Movement disorders |
| Mayo Rochester | Dr. Rodolfo Savica | Clinical |
| UCSF | Dr. Sharon Sha | Clinical trials |
| Trial | Drug | Company | Indication | Enrollment | Status | Primary Endpoint |
|---|---|---|---|---|---|---|
| PROSPER | FNP-223 | Ferrer | PSP | 241 | Active | PSPRS at 52 weeks |
| LOTUS | LY-3372689 | Eli Lilly | PSP | ~100 | Active | PSPRS at 52 weeks |
| MAGNOLIA | LY-3372689 | Eli Lilly | AD | ~200 | Completed | CDR-SB at 52 weeks |
| ASO-001 | IONIS-MAPT | Ionis/Roche | AD | 330 | Completed | Unknown |
| Drug | Company | Selectivity | Brain Penetration | Development Stage |
|---|---|---|---|---|
| FNP-223 | Ferrer | High | Good | Phase 2 (PSP) |
| LY-3372689 | Eli Lilly | High | Good | Phase 2 (PSP/AD) |
| ASN-90 | Asceneuron | High | Good | Phase 1 |
The PROSPER trial is actively following patients with completion expected in November 2026. Results are expected to be announced in late 2026 or early 2027.
Key milestones:
PSPRS - PSP Rating Scale. Neurology. 2003. ↩︎
4R-tauopathies. Acta Neuropathologica. 2020. ↩︎
O-GlcNAcylation and tau in AD. Nature Reviews Neurology. 2024. ↩︎